MA52994A - Peptides à chaîne b de relaxine lipidés modifiés et leur utilisation thérapeutique - Google Patents

Peptides à chaîne b de relaxine lipidés modifiés et leur utilisation thérapeutique

Info

Publication number
MA52994A
MA52994A MA052994A MA52994A MA52994A MA 52994 A MA52994 A MA 52994A MA 052994 A MA052994 A MA 052994A MA 52994 A MA52994 A MA 52994A MA 52994 A MA52994 A MA 52994A
Authority
MA
Morocco
Prior art keywords
relaxin
therapeutic use
modified lipid
chain peptides
peptides
Prior art date
Application number
MA052994A
Other languages
English (en)
French (fr)
Inventor
Elisabetta Bianchi
Olivier Duclos
Stéphane Illiano
Raffaele Ingenito
Paola Magotti
Sergio Mallart
Claire Minoletti-Hochepied
Alessia Santoprete
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of MA52994A publication Critical patent/MA52994A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/64—Relaxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2221—Relaxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MA052994A 2018-01-31 2019-01-30 Peptides à chaîne b de relaxine lipidés modifiés et leur utilisation thérapeutique MA52994A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP18305094 2018-01-31

Publications (1)

Publication Number Publication Date
MA52994A true MA52994A (fr) 2021-05-05

Family

ID=61223862

Family Applications (1)

Application Number Title Priority Date Filing Date
MA052994A MA52994A (fr) 2018-01-31 2019-01-30 Peptides à chaîne b de relaxine lipidés modifiés et leur utilisation thérapeutique

Country Status (29)

Country Link
US (3) US10961295B2 (cg-RX-API-DMAC7.html)
EP (1) EP3746467B1 (cg-RX-API-DMAC7.html)
JP (1) JP7295871B2 (cg-RX-API-DMAC7.html)
KR (1) KR102755938B1 (cg-RX-API-DMAC7.html)
CN (1) CN111770934B (cg-RX-API-DMAC7.html)
AR (1) AR114325A1 (cg-RX-API-DMAC7.html)
AU (1) AU2019214358B2 (cg-RX-API-DMAC7.html)
BR (1) BR112020014834A2 (cg-RX-API-DMAC7.html)
CA (1) CA3089657A1 (cg-RX-API-DMAC7.html)
CO (1) CO2020008308A2 (cg-RX-API-DMAC7.html)
DK (1) DK3746467T3 (cg-RX-API-DMAC7.html)
ES (1) ES3058633T3 (cg-RX-API-DMAC7.html)
FI (1) FI3746467T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20260016T1 (cg-RX-API-DMAC7.html)
IL (2) IL276170B2 (cg-RX-API-DMAC7.html)
LT (1) LT3746467T (cg-RX-API-DMAC7.html)
MA (1) MA52994A (cg-RX-API-DMAC7.html)
MX (1) MX2020008096A (cg-RX-API-DMAC7.html)
MY (1) MY199821A (cg-RX-API-DMAC7.html)
NZ (1) NZ766762A (cg-RX-API-DMAC7.html)
PH (1) PH12020551118A1 (cg-RX-API-DMAC7.html)
PL (1) PL3746467T3 (cg-RX-API-DMAC7.html)
PT (1) PT3746467T (cg-RX-API-DMAC7.html)
RS (1) RS67606B1 (cg-RX-API-DMAC7.html)
SG (1) SG11202006903WA (cg-RX-API-DMAC7.html)
SI (1) SI3746467T1 (cg-RX-API-DMAC7.html)
TW (1) TWI763972B (cg-RX-API-DMAC7.html)
UY (1) UY38069A (cg-RX-API-DMAC7.html)
WO (1) WO2019149782A1 (cg-RX-API-DMAC7.html)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201912034UA (en) 2017-02-08 2020-02-27 Bristol Myers Squibb Co Modified relaxin polypeptides comprising a pharmacokinetic enhancer and uses thereof
WO2019149781A1 (en) * 2018-01-31 2019-08-08 Sanofi Modified lipidated relaxin b chain peptides and their therapeutic use
MY199821A (en) 2018-01-31 2023-11-23 Sanofi Sa Modified lipidated relaxin b chain peptides and their therapeutic use
KR20240118914A (ko) 2021-01-20 2024-08-05 바이킹 테라퓨틱스 인코포레이티드 대사 및 간 질환 치료를 위한 조성물 및 방법
WO2023028008A2 (en) * 2021-08-23 2023-03-02 River 2 Renal Corp. Combination of relaxin and vasopressin analogues for treatment of renal disorders or conditions
CA3231953A1 (en) 2021-09-15 2023-03-23 Brian Lian Compositions and methods for the treatment of metabolic and liver disorders
WO2023086913A2 (en) 2021-11-11 2023-05-19 Tectonic Therapeutic, Inc. Relaxin-2 fusion protein analogs and methods of using same
CN115998842B (zh) * 2022-09-02 2025-08-26 郑州大学第一附属医院 一种逆转肝星形细胞激活的仿生纳米药物及其应用
EP4713001A2 (en) 2023-05-18 2026-03-25 Tectonic Operating Company, Inc. Relaxin-2 fusion protein analogs and methods of using same
KR20250054870A (ko) * 2023-10-16 2025-04-24 (주)케어젠 피부 상태 개선 활성을 갖는 펩타이드 및 이의 용도

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110288011A1 (en) * 2008-12-05 2011-11-24 Jean-Paul Castaigne Peptide therapeutic conjugates and uses thereof
EP2460527A1 (en) * 2010-01-21 2012-06-06 Sanofi Pharmaceutical composition for treating a metabolic syndrome
EP2524915A1 (en) * 2011-05-20 2012-11-21 Sanofi 2-Amino-3-(imidazol-2-yl)-pyridin-4-one derivatives and their use as VEGF receptor kinase inhibitors
AU2012280474A1 (en) * 2011-07-01 2014-01-16 Bayer Intellectual Property Gmbh Relaxin fusion polypeptides and uses thereof
TW201315739A (zh) * 2011-07-01 2013-04-16 拜耳智慧財產有限公司 鬆弛素(relaxin)融合多肽類及其用途
AU2012291972B2 (en) * 2011-08-04 2017-03-09 Pharis Biotec Gmbh Process for preparing human relaxin-2
WO2013177529A1 (en) * 2012-05-24 2013-11-28 Angion Biomedica Corp. Relaxin-like compounds and uses thereof
WO2015038938A1 (en) 2013-09-13 2015-03-19 The California Institute For Biomedical Research Modified therapeutic agents and compositions thereof
CA2945838C (en) * 2014-04-17 2022-08-16 The Florey Institute Of Neuroscience And Mental Health Modified relaxin b chain peptides
HUE052977T2 (hu) * 2014-04-22 2021-06-28 Txp Pharma Gmbh Elágazó szénláncú aminosav-próbával rendelkezõ peptid analóg(ok)
SG10201912034UA (en) * 2017-02-08 2020-02-27 Bristol Myers Squibb Co Modified relaxin polypeptides comprising a pharmacokinetic enhancer and uses thereof
TW201934572A (zh) * 2018-01-31 2019-09-01 法商賽諾菲公司 經修飾之鬆弛素b鏈胜肽及其治療用途
MY199821A (en) 2018-01-31 2023-11-23 Sanofi Sa Modified lipidated relaxin b chain peptides and their therapeutic use
WO2019149781A1 (en) * 2018-01-31 2019-08-08 Sanofi Modified lipidated relaxin b chain peptides and their therapeutic use
TWI844709B (zh) * 2019-07-31 2024-06-11 美商美國禮來大藥廠 鬆弛素(relaxin)類似物及其使用方法
WO2023028008A2 (en) * 2021-08-23 2023-03-02 River 2 Renal Corp. Combination of relaxin and vasopressin analogues for treatment of renal disorders or conditions

Also Published As

Publication number Publication date
PL3746467T3 (pl) 2026-04-13
PT3746467T (pt) 2026-01-13
US20240218042A1 (en) 2024-07-04
CN111770934B (zh) 2024-10-18
US10961295B2 (en) 2021-03-30
AR114325A1 (es) 2020-08-19
AU2019214358A1 (en) 2020-08-20
CA3089657A1 (en) 2019-08-08
JP2021512099A (ja) 2021-05-13
US20190233494A1 (en) 2019-08-01
SI3746467T1 (sl) 2026-02-27
DK3746467T3 (da) 2026-01-12
RU2020126210A (ru) 2022-02-28
CN111770934A (zh) 2020-10-13
IL276170B2 (en) 2025-03-01
US11725036B2 (en) 2023-08-15
SG11202006903WA (en) 2020-08-28
IL276170B1 (en) 2024-11-01
UY38069A (es) 2019-08-30
TWI763972B (zh) 2022-05-11
KR102755938B1 (ko) 2025-01-20
NZ766762A (en) 2026-03-27
FI3746467T3 (fi) 2026-01-16
US20210292387A1 (en) 2021-09-23
MX2020008096A (es) 2020-09-24
TW201940505A (zh) 2019-10-16
EP3746467B1 (en) 2025-10-08
HRP20260016T1 (hr) 2026-02-27
RS67606B1 (sr) 2026-01-30
BR112020014834A2 (pt) 2020-12-08
CO2020008308A2 (es) 2020-10-30
MY199821A (en) 2023-11-23
KR20200116085A (ko) 2020-10-08
AU2019214358B2 (en) 2023-05-25
LT3746467T (lt) 2026-01-26
IL316406A (en) 2024-12-01
IL276170A (en) 2020-09-30
ES3058633T3 (en) 2026-03-12
WO2019149782A1 (en) 2019-08-08
EP3746467A1 (en) 2020-12-09
PH12020551118A1 (en) 2021-07-05
JP7295871B2 (ja) 2023-06-21

Similar Documents

Publication Publication Date Title
EP3448412A4 (en) ANTI-HUMAN-VISTA ANTIBODIES AND USE THEREOF
MA52284A (fr) Anticorps anti-hla-g et leur utilisation
EP3523332A4 (en) ANTI-HUMAN 4-1 BB ANTIBODY AND ITS USE
EP3875484A4 (en) ANTIBODY DIRECTED TO CLL1 AND USE THEREOF
EP3423038A4 (en) Matrix bound nanovesicles and their use
EP3430058A4 (en) MULTISPECIFIC FAB FUSION PROTEINS AND USES THEREOF
SI3746467T1 (sl) Modificirani lipidirani peptidi relaksina z verigo B in njihova terapevtska uporaba
EP3399989A4 (en) ANTI-LAG3 ANTIBODIES AND ANTIGEN-BINDING FRAGMENTS
MA52285A (fr) Anticorps multispécifiques et leur utilisation
MA49512A (fr) Protéines de liaison à l'antigène anti-papillomavirus humain et leurs méthodés d'utilisation
EP3354661A4 (en) COMPLETELY HUMAN ANTIBODY AGAINST HUMANESE CD137 AND USE THEREOF
EP3708661A4 (en) THERAPEUTIC ENZYMFUSION PROTEIN WITH A NEW STRUCTURE AND ITS USE
EP3442567A4 (en) ANTI-PSMA ANTIBODIES AND USE THEREOF
EP3960756A4 (en) FLAGELLIN FUSION PROTEIN AND USE THEREOF
EP3962956A4 (en) ANTI-HVEM ANTIBODIES AND USE THEREOF
HUE055231T2 (hu) Inzulint tartalmazó gyógyászati készítmények
IL290660A (en) Medical protein concentrates
EP3587440A4 (en) HUMAN HIGH PROTEIN INFFINITY PD-L1 PEPTIDE AND USES THEREOF
EP3684789A4 (en) ZEIN ENRICHED AND DEFEATED PROTEIN
EP3882277A4 (en) FUSION PROTEIN AND USE THEREOF
EP4013440A4 (en) THERAPEUTIC PEPTIDES
EP3570867A4 (en) THERAPEUTIC PEPTIDES AND NEUROPROTECTORS
EP3883965A4 (en) ANTI-IL-25 ANTIBODIES AND USE THEREOF
EP3723781A4 (en) PEPTIDES AND OTHER AGENTS FOR PAIN TREATMENT AND PAIN SENSITIVITY
EP3302531A4 (en) IMMUNO-TOLERANT AND NON-INHIBITORY ELASTIC SIMILAR RECOMBINANT PEPTIDES AND METHOD OF USE